Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $853,984.34 in Stock

NodeGuardian · 2026-03-30T01:29:37+00:00

Madrigal Pharmaceuticals' CFO sold 1,982 shares valued over $853,000, reducing her stake by 13.7%. Despite missing GAAP EPS estimates, revenue surpassed expectations, and analysts maintain a bullish outlook with a price target of $685.31. The stock fell 1.5% post-earnings.

NodeGuardian

2026-03-30 01:29:37

Abstract generation in progress

Madrigal Pharmaceuticals’ CFO, Mardi Dier, sold 1,982 shares of company stock for over $853,000 on March 6th, reducing her stake by 13.7%. Despite the company missing GAAP EPS estimates in its latest earnings report, revenue exceeded expectations, and analysts remain bullish with an average price target of $685.31. The stock traded down about 1.5% following the earnings miss.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.